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Abstract
Rationale: The comparative efficacy and cost-effectiveness of constraint-induced and 
multi-modality aphasia therapy in chronic stroke are unknown.
Aims and hypotheses: In the COMPARE trial we aim to determine whether Multi-
Modal Aphasia Treatment (M-MAT) and Constraint-Induced Aphasia Therapy Plus 
(CIAT-Plus) are superior to usual care (UC) for chronic post-stroke aphasia. Primary 
hypothesis: CIAT-Plus and M-MAT will reduce aphasia severity (Western Aphasia 
Battery-Revised Aphasia Quotient [WAB-R-AQ]) compared with UC: CIAT-Plus 
superior for moderate aphasia; M-MAT superior for mild and severe aphasia.
Sample size estimates: 216 participants (72 per arm) will provide 90% power to 
detect a 5-point difference on the WAB-R-AQ between CIAT-Plus or M-MAT and 
UC at α = 0.05.
Methods and design: Prospective, randomized, parallel group, open-label, assessor 
blinded trial. Participants: Stroke >6 months; aphasia severity categorised using 
WAB-AQ. Computer-generated blocked and stratified randomization by aphasia 
severity (mild, moderate, severe), to 3 arms: CIAT-Plus, M-MAT (both 30 hours 
therapy over 2 weeks); UC (self-reported usual community care). 
Study outcomes: WAB-R-AQ immediately post intervention. Secondary outcomes: 
WAB-R-AQ at 12-week follow-up; naming scores, discourse measures, 
Communicative Effectiveness Index, Scenario Test, and Stroke and Aphasia Quality 
of Life Scale-39g immediately and at 12 weeks post intervention; incremental cost-
effectiveness ratios compared with UC at 12 weeks.
Discussion: This trial will determine whether CIAT-Plus and M-MAT are superior 
and more cost-effective than UC in chronic aphasia. Participant subgroups with the 
greatest response to CIAT-Plus and M-MAT will be described. 
Key words
Aphasia therapy, stroke, multimodal, constraint, intensity, rehabilitation, randomised 
controlled trial
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Introduction and rationale:
Aphasia, an acquired language disability, impacts understanding speech, reading, 
writing, and speaking. Aphasia affects one third of stroke survivors1, with significant 
negative impacts on mental health2 and quality of life3. People with stroke-aphasia 
vary widely in aphasia type and severity, and co-morbid cognitive impairments. This 
variability has underpinned the development of a range of aphasia treatments. In the 
recent Cochrane review, analysis of 57 aphasia therapy trials revealed statistically 
significant treatment effects for functional communication, reading, writing, and 
expressive language4. Significant benefits were found for high intensity, high dose, or 
long duration interventions, although these schedules had a larger drop-out rate4. 
Benefits were not maintained at 3-6 month follow-up4. The review results are limited 
by small numbers of randomized participants and inferior study quality. Recently, 
Breitenstein et al. compared intensive language therapy (30 hours over 3 weeks) to 
usual care in 156 people with chronic (>6 months) post-stroke aphasia and found 
significantly improved verbal communication (d-0.58) immediately post-intervention 
and at 6-month follow-up5.
Constraint-Induced Aphasia Therapy (CIAT) is an intensive, high-dose intervention 
aimed at improving verbal output in a group setting of 2-3 patients6. CIAT assumes 
that people with aphasia experience a worsening of symptoms through non-use of 
language and a reliance on nonverbal communication (e.g., gesture, drawing). 
Therefore, CIAT focuses on speaking activities and nonverbal communication is 
discouraged. CIAT-Plus is an enhanced protocol including written cues and home 
practice6. 
Multi-Modality Aphasia Therapy (M-MAT) also aims to improve verbal output but 
specifically utilises nonverbal strategies7 that may be useful if speaking fails after 
treatment. Evidence from a pilot study7 and a systematic review8 suggest CIAT-Plus 
and M-MAT may be equally efficacious. However, high quality comparative-
effectiveness evidence is required to refine treatment prescription and describe 
potential cost-effectiveness.
Methods:
The aims of the COMPARE trial are to determine whether CIAT-Plus and M-MAT 
are superior to usual care (UC) for people with chronic aphasia and determine if 
CIAT-Plus or M-MAT are superior for particular subgroups. The primary hypothesis 
is that compared to UC, both CIAT-Plus and M-MAT will result in reduced aphasia 
severity (≥5-point improvement on the Western Aphasia Battery-Revised Aphasia 
Quotient (WAB-R-AQ))9 immediately post intervention. CIAT-Plus is predicted to be 
superior for moderate aphasia and M-MAT superior for both mild and severe 
aphasia7. The potential cost-effectiveness of these interventions over UC is assessed.
Design:
COMPARE is a three-armed prospective, single-blinded multicenter, randomized 
controlled trial with primary outcome immediately following treatment and follow-up 
12 weeks after treatment (see Figure 1) with an intention-to-treat analysis. The 
protocol is aligned with the CONSORT extension for non-pharmacologic 
interventions10, is registered with the Australian and New Zealand Clinical Trials 
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Registry (12615000618550), and has ethics approval from La Trobe University, Gold 
Coast University Hospital (Queensland, Australia), and each participating hospital 
site’s ethics committee.
Figure 1 about here
Patient population - inclusion and exclusion criteria:
Stroke >6 months; aphasia severity categorised using WAB-R-AQ. See Table 1 for 
full details.
Table 1 about here
Randomisation:
Each participant is assessed for baseline aphasia severity, (WAB-R-AQ mild= 93.7-
62.6; Moderate= 62.5-31.3; Severe< 31.2) and allocated to a group of 2-3 participants 
with the same severity level. Each group is randomized to one of three arms. The 
randomization schedule was created by an independent statistician, using a computer-
generated permuted blocked procedure and allocation ratio of 1:1:1.
 
Intervention:
CIAT-Plus and M-MAT interventions are provided by qualified, study-trained speech 
pathologists for 3 hours per weekday for 2 weeks (30 hours) with 15-minute daily 
home practice tasks monitored via written log/carer report. All assessment staff are 
blinded to group allocation.
Arm 1: UC
The UC control group undergo aphasia therapy at the type and frequency available in 
the community at the time of recruitment and randomisation (estimated at <2 
hours/week). Participants keep a study-specific diary of therapy activity. 
Arm 2: CIAT-Plus
In CIAT-Plus, participants produce functional words, phrases and sentences in 
response to pictured object and action cards in communication games. Visual barriers 
between participants discourage non-verbal communication. Therapists cue and shape 
verbal responses, providing verbal models to repeat and written words for participants 
to read aloud. As performance improves, participant responses are progressively 
shaped from single words (e.g., “Coffee?”) to elaborated sentences (e.g., “John, do 
you want a large, black coffee?”). 
Arm 3: M-MAT
M-MAT also involves communication game activities, in a group setting, but there 
are no visual barriers, and participants have access to pen and paper. Therapists cue 
and shape verbal and multimodal responses from participants involving gestures, 
written words, simple drawings, and verbal repetitions of the targets. 
Therapists complete daily therapy logs (REDCap11 Case Report Form) for each 
participant, including content and duration of therapy sessions, nature of home 
exercise, and self-reported fatigue or distress. CIAT-Plus and M-MAT sessions are 
video recorded and monitored. Protocol deviations are addressed with the therapist 
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and documented in REDCap. 
Primary outcome:
Required study assessments with timelines are outlined in Figure 1. The primary 
outcome is the WAB-R-AQ score assessed by a blinded assessor immediately post-
intervention. The WAB-R-AQ is a reliable measure of language impairment, is 
sensitive to change, and forms a recommended core outcome for aphasia intervention 
trials9,12.
Secondary outcomes:
Secondary outcomes include: aphasia severity (WAB-R-AQ9 score at 12-week 
follow-up); health related quality of life (SAQoL-3913, EQ-5D-3L14), multimodal 
communication (Scenario Test15) and functional communication (Communication 
Effectiveness Index16) immediately and at 12 weeks post-intervention. A resource use 
and cost questionnaire is collected at 12 week follow-up. 
Data monitoring body:
Participants are monitored for adverse events (AEs) throughout this trial. AEs relating 
to a new diagnosis or worsening of clinical symptoms are reported up to the follow-up 
assessment. An independent Data Safety Monitoring Committee reviews safety data 
annually (or earlier if necessary).
Sample size estimates:
After adjusting for the clustering effect of group therapy, 216 participants will provide 
90% power to detect a 5-point difference on the WAB-AQ at α =0.05.
Statistical analyses:
Separate Linear Mixed Models (LMMs) will be used to analyse differences between 
M-MAT and UC, and CIAT-Plus and UC on each outcome measure immediately and 
at 12 weeks post-intervention. The LMM for WAB-R-AQ will assess the differences 
in efficacy between M-MAT and CIAT-Plus. All analyses will control for baseline 
aphasia severity (fixed effect) and for the clustering effect of treatment groups 
(random effect). Details will be published in a formal statistical analysis plan, prior to 
trial completion.
Economic evaluation
Resource utilisation is captured using a standardized approach from a societal 
perspective with the main focus on the health sector and costs to individuals. Costs 
involved in the organisation and delivery of the intervention are included. Incremental 
cost-effectiveness ratios will be reported as the net cost per unit improvement in the 
primary and secondary outcomes. Sensitivity and uncertainty analyses will be 
undertaken. 
Study organization and funding:
The COMPARE trial is managed by the management committee comprising all chief 
investigators and trial managers and supported by a National Health and Medical 
Research Council Project grant (#1083010). 
Summary and conclusion:
COMPARE is the first trial to assess the comparative efficacy of constraint induced 
Page 6 of 8International Journal of Stroke
For Review Only
and multi-modal aphasia therapies for chronic post-stroke aphasia. Results will enable 
more effective treatment prescription. Cost-effectiveness information will provide 
support for business cases in adapting current management practice and policy for 
chronic aphasia. Since trial commencement, 135 participants have been randomized. 
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Table 1. Eligibility criteria
Inclusion criteria
Over the age of 18 with documented stroke and resultant aphasia of any type 
A WAB-AQ score <93.8 
Medically stable at recruitment
Fluent in English prior to stroke
Independent toileting
Carer/significant other able to participate in assessments
Exclusion criteria
Previous history of non-stroke neurological event 
Severe apraxia of speech or dysarthria on the Apraxia of Speech Rating Scale
Current diagnosis of major clinical depression or other mental health condition that 
may affect adherence to the study protocol
Uncorrected sensory loss preventing participation in communication assessments 
and treatments
Serious medical condition prior to their stroke (including malignancies, psychiatric, 
behavioural or drug-dependency problems) likely to influence participation or 
prevent adherence to protocol 
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